Conclusions: In this nationwide cohort, adding GLP-1 RAs to insulin therapy in patients with T2D was associated with significantly lower risks of cardiovascular events, major microvascular complications, and all-cause mortality compared with adding DPP-4 inhibitors. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.